文献速递妇科

合理分诊使晚期卵巢癌初次减瘤术并发症与间隔手术相当

Appropriate triage allows aggressive primary debulking surgery with rates of morbidity and mortality comparable to interval surgery after chemotherapy.
PubMed 文献 · Gynecol Oncol · 2020-12-31

本研究纳入334例晚期上皮性卵巢癌患者,采用前瞻性分诊算法决定初次减瘤术(PDS)或新辅助化疗后间隔减瘤术(IDS),并用逆概率加权调整混杂。结果显示PDS组虽然手术更复杂,但30天3级以上并发症、90天死亡率与IDS组相当,完全切除率相似,且3年总生存更高。

要点

  • 前瞻性分诊算法使69.5%晚期卵巢癌患者接受PDS。
  • PDS组30天3级以上并发症与IDS组相当(加权18.3% vs 12.9%)。
  • PDS组3年总生存优于IDS组(加权64.1% vs 42.6%)。

核心结论

  • 使用经过验证的分诊策略可使约70%晚期上皮性卵巢癌患者接受PDS,其并发症与死亡率低且与IDS相当,完全切除率相似且总生存更优。

研究设计与样本

  • 回顾性队列研究,纳入2012年1月至2016年7月接受PDS或IDS的晚期上皮性卵巢癌患者共334例,使用前瞻性分诊算法指导治疗选择,并采用逆概率治疗加权(IPTW)调整协变量不平衡。

主要发现

  • 334例中232例(69.5%)接受PDS,102例(30.5%)分诊至IDS。
  • PDS组较IDS组更年轻(63.9 vs 67.5岁,P=0.01),低白蛋白比例更低(16.8% vs 32.4%,P<0.001),中位手术时间更长(315 vs 263分钟,P<0.001),高复杂度手术更多(27.2% vs 11.8%)、低复杂度手术更少(18.5% vs 36.3%),P<0.001。
  • 完全切除率(62.5% vs 66.7%,P=0.47)和满意减瘤率(95.3% vs 98.0%,P=0.36)两组相当。
  • 30天3级以上并发症IPTW调整后为18.3% vs 12.9%(P=0.22),90天死亡率IPTW调整后为2.2% vs 3.8%(P=0.42),住院时间(P=0.29)和术后化疗实施(P=0.83)两组相当。
  • 3年总生存PDS组更高(IPTW调整后64.1% vs 42.6%,P=0.001)。

临床怎么用

  • 在考虑PDS与新辅助化疗时,应使用经过验证的分诊系统筛选适合PDS的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Morbidity and mortality (M/M) after primary debulking surgery (PDS) is often cited as a rationale for neoadjuvant chemotherapy and interval debulking surgery (IDS). We tested if using an evidence-based algorithm to identify patients fit for surgery would reduce M/M after PDS to that seen after IDS. METHODS: We included women who underwent PDS or IDS for advanced epithelial ovarian cancer (EOC) (1/2012-7/2016) guided by the use of a prospective triage algorithm. Outcomes were compared after applying inverse-probability of treatment weighting (IPTW) to adjust for covariate imbalance. RESULTS: Of 334 included patients, 232 (69.5%) underwent PDS and 102 (30.5%) were triaged to IDS. Relative to IDS group, PDS patients were younger (63.9 vs 67.5 years, P=0.01), were less likely to have low albumin (16.8% vs. 32.4%, P<0.001), had longer median operative times (315 vs 263 min, P <0.001), more high complexity surgeries and fewer low complexity surgeries (27.2% vs. 11.8% and 18.5% vs 36.3% respectively, P<0.001). The rates of the following outcomes were comparable for PDS and IDS, respectively: successful cytoreduction (complete, 62.5% vs 66.7%, P=0.47 and optimal, 95.3% vs 98.0%, P=0.36), 30-day grade 3+ complications (IPTW-adjusted 18.3% vs. 12.9%, P=0.22), 90-day mortality (IPTW-adjusted, 2.2% vs. 3.8%, P=0.42), length of hospitalization (P=0.29), and postoperative chemotherapy delivery (P=0.83). 3-year overall survival was higher for PDS group (IPTW-adjusted 64.1% vs. 42.6%, P=0.001). CONCLUSIONS: Use of our validated triage strategy allowed us to offer 70% of women with advanced EOC PDS surgery. Despite more complex surgery, M/M after this approach is low and comparable to IDS, with similar rates of complete resection and superior OS. Use of a validated triage system should be utilized when considering PDS vs neoadjuvant chemotherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Narasimhulu DM, Thannickal A, Kumar A, et al. Appropriate triage allows aggressive primary debulking surgery with rates of morbidity and mortality comparable to interval surgery after chemotherapy. Gynecol Oncol. 2020. PMID: 33390326. doi:10.1016/j.ygyno.2020.12.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。